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reveals reduced ADCs in responding tumors, with the percent change in 
ADC from baseline correlating with deeper RANO responses. CONCLU-
SION: DWI analysis reveals reductions in ADC values that correlates with 
treatment response and a shift toward more normal cellularity in tumors 
treated with DAY101. Changes in ADC may represent a novel imaging bio-
marker, reflecting biological response to DAY101 treatment.
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INTRODUCTION: Magnetic Resonance Imaging (MRI) is routinely 
used in the assessment of children’s brain tumours. Reduced diffusion and 
increased perfusion on MRI are commonly associated with higher grade 
but there is a lack of quantitative data linking these parameters to survival. 
Machine learning is increasingly being used to develop diagnostic tools but 
its use in survival analysis is rare. In this study we combine quantitative 
parameters from diffusion and perfusion MRI with machine learning to 
develop a model of survival for paediatric brain tumours. METHOD: 69 
children from 4 centres (Birmingham, Liverpool, Nottingham, Newcastle) 
underwent MRI with diffusion and perfusion (dynamic susceptibility con-
trast) at diagnosis. Images were processed to form ADC, cerebral blood 
volume (CBV) and vessel leakage correction (K2) parameter maps. Param-
eter mean, standard deviation and heterogeneity measures (skewness and 
kurtosis) were calculated from tumour and whole brain and used in iterative 
Bayesian survival analysis. The features selected were used for k-means clus-
tering and differences in survival between clusters assessed by Kaplan-Meier 
and Cox-regression.  RESULTS: Bayesian analysis revealed the 5 top fea-
tures determining survival to be tumour volume, ADC kurtosis, CBV mean, 
K2 mean and whole brain CBV mean. K-means clustering using these fea-
tures showed two distinct clusters (high- and low-risk) which bore signifi-
cantly different survival characteristics (Hazard Ratio = 5.6). DISCUSSION 
AND CONCLUSION: Diffusion and perfusion MRI can be used to aid the 
prediction of survival in children’s brain tumours. Tumour perfusion played 
a particularly important role in predicting survival despite being less rou-
tinely measured than diffusion.
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BACKGROUND: Patients with chiasmatic-hypothalamic low grade 
glioma (CHLGG) have frequent MRIs with gadolinium based contrast 
agents (GBCA) for disease monitoring. Cumulative gadolinium depos-
ition in children is a potential concern. The purpose of this research is to 
establish whether MRI with GBCA is necessary for determining tumor 
progression in children with CHLGG.  METHODS: Children with pro-
gressive CHLGG were identified from Texas Children’s Cancer Center be-
tween 2005–2019. Pre- and post-contrast MRI sequences were separately 
reviewed by one neuroradiologist who was blinded to the clinical course. 
Three dimensional measurements and tumor characteristics were collected. 
Radiographic progression was defined as a 25% increase in size (product of 
two largest dimensions) compared to baseline or best response after initi-
ation of therapy. RESULTS: A total of 28 patients with progressive CHLGG 
including 683 MRIs with GBCA (mean 24 MRIs/patient; range: 10–43 
MRIs) were reviewed. No patients had a diagnosis of NF1. Progression was 
observed 92 times, 91 (98.9%) on noncontrast and 90 (97.8%) on contrast 
imaging. Sixty-seven radiographic and/or clinical progressions necessitating 
management changes were identified in all (100%) noncontrast sequences 
and 66 (98.5%) contrast sequences. Tumor growth >2 mm in any dimension 
was identified in 184/187(98.4%) on noncontrast and 181/187(96.8%) with 
contrast imaging. Non primary metastatic disease was seen in seven patients 
(25%), which were better visualized on contrast imaging in 4 (57%). CON-
CLUSION: MRI without GBCA effectively identifies patients with progres-
sive disease. One should consider eliminating contrast in imaging of children 
with CHLGG with GBCA reserved for monitoring those with metastatic 
disease.
IMG-08. UNUSUAL IMAGING FINDINGS IN TWO CASES OF 
PAEDIATRIC LOW GRADE GLIOMA
Vickyanne Carruthers1, Kathryn Siddle1, Gail Halliday1, Simon Bailey1,2, 
and Rebecca Hill1; 1Newcastle Upon Tyne Hospitals Trust, Newcastle 
Upon Tyne, United Kingdom, 2Sir James Spence Institute of Child Health, 
Newcastle Upon Tyne, United Kingdom
Low grade gliomas (LGG), including pilocytic astrocytoma (PCA), are 
the commonest paediatric brain tumours and their behaviour is well under-
stood, typically following a benign course. BRAF fusion is common, par-
ticularly in PCA of the cerebellum and optic pathway. Here we present two 
patients whose LGG behaved in an unusual fashion. The first patient who 
was treated 6 years previously on LGG2 with vincristine and carboplatin 
for a tectal plate lesion was identified on routine imaging to have local tu-
mour progression and underwent completion staging. This showed a new 
enhancing soft tissue abnormality within the spinal cord at the level of L2. 
Due to radiological dubiety both lesions were biopsied for histological and 
molecular analysis, confirming LGG of the tectal plate and finding the spinal 
lesion to be a myxopapillary ependymoma. The second patient presented 
with acute hydrocephalus following a 2 year history of neurocognitive im-
pairments. He was found to have a large, complex tumour centred in and 
expanding the bodies of both lateral ventricles with significant mass effect. 
Radiologically this was most in keeping with a central neurocytoma but 
histological analysis confirmed it to be a PCA with KIAA1549-BRAF fusion. 
The first case demonstrates the utility of molecular analysis in confirming 
two distinct tumour types in one patient, in a situation where metastasis 
would not be expected and would significantly alter treatment and prog-
nosis. The second is an example of how imaging can be misleading in a 
KIAA1549-BRAF fused PCA presenting as an intraventricular mass.
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Optimizing the conduct of clinical trials for diffuse intrinsic pontine 
glioma (DIPG) involves use of consistent, objective disease assessments and 
standardized response criteria. The Response Assessment in Pediatric Neuro-
Oncology (RAPNO) committee, an international panel of pediatric and adult 
neuro-oncologists, clinicians, radiologists, radiation oncologists, and neuro-
surgeons, was established to address unique challenges in assessing response 
in children with CNS tumors. A subcommittee of RAPNO was formed to 
specifically address response assessment in children and young adults with 
DIPG and to develop a consensus on recommendations for response assess-
ment. Distinct issues related to the response assessment of DIPG include its 
definition and recent molecular classifications, dearth of imaging response 
data, the phenomena of pseudoprogression, and measuring response in the 
era of focal drug delivery. The committee has recommended response be 
assessed using magnetic resonance imaging (MRI) of brain and spine, neuro-
logic examination, and use of supportive medication, i.e. steroids and anti-
angiogenic agents. Clinical imaging standards and imaging quality control 
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